anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Osteoporosis 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Chronic Kidney Disease 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Vitamin D supplementation for the treatment of COVID‐19: a living systematic review
1. Aged 80 and over 80+ years 2. COVID-19 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Digital interventions for the management of chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Exercise training for bronchiectasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Bronchiectasis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
High versus low positive end‐expiratory pressure (PEEP) levels for mechanically ventilated adult patients with acute lung injury and acute respiratory distress syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Intubation 6. Intensive Care 7. Mechanical ventilation 8. Aged 65-79 years 9. Acute Lung Injury 10. Acute Respiratory Distress Syndrome 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prevention of depression in adults with long‐term physical conditions
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. General Physical Condition 5. Young Adult 19-24 years 6. Chronic Disease 7. Aged 65-79 years
Provide patient population that should be included in the study
Video games for people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acute Schizophrenia-like Psychotic Disorder 5. Young Adult 19-24 years 6. Schizophrenia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Rehabilitation following surgery for flexor tendon injuries of the hand
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Injury Of Flexor Tendon Of Hand 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Urgent‐start peritoneal dialysis versus conventional‐start peritoneal dialysis for people with chronic kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Peritoneal Dialysis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Chronic Kidney Disease 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Maintenance treatment with antipsychotic drugs for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Schizophrenic Psychoses 7. Aged 65-79 years
Provide patient population that should be included in the study
Psychosocial interventions for conversion and dissociative disorders in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Conversion disorder 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Dissociative Disorder 7. Aged 65-79 years
Provide patient population that should be included in the study
Repositioning for pressure injury prevention in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hospitalization 6. Aged 65-79 years 7. Living In Nursing Home
Provide patient population that should be included in the study
Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal women
1. Aged 80 and over 80+ years 2. Faecal incontinence 3. Adult 19-44 years 4. Urinary Continence 5. Middle Aged 45-64 years 6. Postpartum 7. Young Adult 19-24 years 8. Antenatal 9. Bowels: Fully Continent 10. Urinary Incontinence 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐steroidal anti‐inflammatory drugs for acute low back pain
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Acute Low Back Pain 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Subcuticular sutures for skin closure in non‐obstetric surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Epidural corticosteroid injections for lumbosacral radicular pain
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Aged 65-79 years 5. Sciatica
Provide patient population that should be included in the study
Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit
1. Delirium 2. Not reported
Provide patient population that should be included in the study
Percutaneous pinning for treating distal radial fractures in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Fracture Of Distal End Of Radius 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacological interventions for treatment‐resistant depression in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Treatment-resistant depression 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Transcutaneous electrical nerve stimulation (TENS) for chronic neck pain
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Chronic Neck Pain 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Modafinil for people with schizophrenia or related disorders
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Perioperative restrictive versus goal‐directed fluid therapy for adults undergoing major non‐cardiac surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Treatments for primary delusional infestation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Primary Delusions 6. Aged 65-79 years 7. Delusions Of Infestation 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for prodromal stage of psychosis
1. Psychosis 2. Disease prodromal stage
Provide patient population that should be included in the study
Surgical versus conservative interventions for treating acromioclavicular dislocation of the shoulder in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Dislocation Of Acromioclavicular Joint 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Acetylsalicylic acid (aspirin) for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Rigid dressings versus soft dressings for transtibial amputations
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Amputated Below Knee 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease 5. Chronic Bronchitis
Provide patient population that should be included in the study
Conservative management following closed reduction of traumatic anterior dislocation of the shoulder
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Anterior Dislocation Of Shoulder Joint 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Effects Of High Altitude 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Peer support for people with schizophrenia or other serious mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Mental disorder 6. Schizophrenia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Subfascial endoscopic perforator surgery (SEPS) for treating venous leg ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Venous leg ulcer
Provide patient population that should be included in the study
Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Benign prostatic hyperplasia 5. Lower urinary tract symptoms 6. Aged 65-79 years
Provide patient population that should be included in the study
Immunonutrition for acute respiratory distress syndrome (ARDS) in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Mechanical ventilation 5. Acute Respiratory Distress Syndrome 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Subacromial decompression surgery for rotator cuff disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Disorder Of Rotator Cuff 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Deep brain stimulation for dystonia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Dystonia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Effects of peri‐operative nonsteroidal anti‐inflammatory drugs on post‐operative kidney function for adults with normal kidney function
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Surgery 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Laryngeal mask airway versus endotracheal tube for percutaneous dilatational tracheostomy in critically ill adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Critical Illness 6. Intensive Care 7. Aged 65-79 years
Provide patient population that should be included in the study
Perioperative alcohol cessation intervention for postoperative complications
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. Administration Of Anesthesia 7. Excessive Drinking 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Chlorpromazine versus piperacetazine for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Antibiotics for exacerbations of chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. COPD Exacerbation 6. Aged 65-79 years
Provide patient population that should be included in the study
Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD)
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Aged 65-79 years 5. Chronic kidney disease-mineral and bone disorder
Provide patient population that should be included in the study
Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Critical Illness 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fluphenazine (oral) versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. General Anesthesia 7. Aged 65-79 years
Provide patient population that should be included in the study
Psychological therapies for treatment‐resistant depression in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Recurrent Depression 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Laparoscopic‐endoscopic rendezvous versus preoperative endoscopic sphincterotomy in people undergoing laparoscopic cholecystectomy for stones in the gallbladder and bile duct
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Bile Duct Stone 9. Gallstones 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation)
1. Aged 80 and over 80+ years 2. Psychosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Aggressive Behavior 6. Young Adult 19-24 years 7. Agitated 8. Aged 65-79 years
Provide patient population that should be included in the study
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. COPD Exacerbation 7. Aged 65-79 years
Provide patient population that should be included in the study
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
1. Schizophrenia 2. Tardive dyskinesia
Provide patient population that should be included in the study
Fitness training for cardiorespiratory conditioning after traumatic brain injury
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Traumatic Brain Injury 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Peritoneal dialysis for acute kidney injury
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Acute Renal Failure 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Personalised asthma action plans for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Asthma
Provide patient population that should be included in the study
Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Fibrin glue for pilonidal sinus disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Pilonidal Sinus Disease 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Intensive case management for severe mental illness
1. Adult 19-44 years 2. Severe mental disorder 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Protease‐modulating matrix treatments for healing venous leg ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Venous leg ulcer
Provide patient population that should be included in the study
Non‐steroidal anti‐inflammatory drugs for sciatica
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Aged 65-79 years 5. Adolescent 13-18 years 6. Sciatica
Provide patient population that should be included in the study
Lung volume reduction surgery for diffuse emphysema
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pulmonary Emphysema
Provide patient population that should be included in the study
Fast‐track cardiac care for adult cardiac surgical patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cardiopulmonary Bypass 6. Cardiac surgery 7. Aged 65-79 years
Provide patient population that should be included in the study
Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Acute Respiratory Distress Syndrome 11. Acute Lung Injury 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Manual therapy and exercise for rotator cuff disease
1. Adult 19-44 years 2. Young Adult 19-24 years 3. Disorder Of Rotator Cuff 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Back schools for acute and subacute non‐specific low‐back pain
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Low back pain 4. Young Adult 19-24 years 5. Acute Low Back Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Risperidone (depot) for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Surgical versus conservative interventions for treating anterior cruciate ligament injuries
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Injury Of Anterior Cruciate Ligament 10. Anterior Cruciate Ligament Tear 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Care delivery and self management strategies for adults with epilepsy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Epilepsy 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Motor control exercise for chronic non‐specific low‐back pain
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Low back pain 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Multi‐disciplinary rehabilitation for acquired brain injury in adults of working age
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Acquired Brain Injury 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Crisis intervention for people with severe mental illnesses
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Rehabilitation for distal radial fractures in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Colles' Fracture 5. Fracture Of Distal End Of Radius 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Early versus delayed dressing removal after primary closure of clean and clean‐contaminated surgical wounds
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Surgery 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Wound Closure 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Social skills programmes for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Cognitive‐behavioural treatment for subacute and chronic neck pain
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Chronic Neck Pain 4. Young Adult 19-24 years 5. Neck Pain
Provide patient population that should be included in the study
Use of plastic adhesive drapes during surgery for preventing surgical site infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Surgery 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Supportive therapy for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Hydrogel dressings for treating pressure ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Pressure ulcer 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Protocolized versus non‐protocolized weaning for reducing the duration of mechanical ventilation in critically ill adult patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Invasive Mechanical Ventilation 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Critical Illness 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Minimally invasive discectomy versus microdiscectomy/open discectomy for symptomatic lumbar disc herniation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Herniated Disc 5. Young Adult 19-24 years 6. Lumbar radiculopathy 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Platelet‐rich therapies for musculoskeletal soft tissue injuries
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Musculoskeletal System Repair 4. Musculoskeletal injury 5. Young Adult 19-24 years 6. Soft Tissue Injury
Provide patient population that should be included in the study
Bronchial thermoplasty for moderate or severe persistent asthma in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Asthma
Provide patient population that should be included in the study
Trifluoperazine versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Enhanced care by generalists for functional somatic symptoms and disorders in primary care
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Somatic symptom disorder 6. Aged 65-79 years
Provide patient population that should be included in the study
User‐held personalised information for routine care of people with severe mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Severe mental disorder 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Traction for low‐back pain with or without sciatica
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Low back pain 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Sciatica
Provide patient population that should be included in the study
Dressings for superficial and partial thickness burns
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Superficial Friction Burn 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Second-degree burn 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Inhaled corticosteroids for subacute and chronic cough in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chronic Cough 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Nurse versus physician‐led care for the management of asthma
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Asthma
Provide patient population that should be included in the study
Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Kidney Stone 6. Aged 65-79 years
Provide patient population that should be included in the study
Totally tubeless, tubeless, and tubed percutaneous nephrolithotomy for treating kidney stones
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Kidney Stone 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Kidney Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for improving health literacy in people with chronic kidney disease
1. Chronic Kidney Disease
Provide patient population that should be included in the study
Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. End Stage Kidney Disease 4. Central Venous Catheter Associated Bloodstream Infection 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Haemodialysis 8. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for minimal change disease in adults with nephrotic syndrome
1. Aged 80 and over 80+ years 2. Nephrotic Syndrome 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Minimal Change Disease 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
1. Aged 80 and over 80+ years 2. Continuous Renal Replacement Therapy 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Acute Renal Failure 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Aldosterone antagonists for people with chronic kidney disease requiring dialysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Kidney Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Continuous Renal Replacement Therapy 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Acute Renal Failure 9. Young Adult 19-24 years 10. Intensive Care 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults
1. Aged 80 and over 80+ years 2. Extracorporeal Shockwave Lithotripsy 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Ureteric Stone 6. Young Adult 19-24 years 7. Kidney Stone 8. Aged 65-79 years
Provide patient population that should be included in the study
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Kidney disease 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Calcium channel blockers for people with chronic kidney disease requiring dialysis
1. Peritoneal Dialysis 2. Chronic Kidney Disease 3. Haemodialysis 4. Renal Dialysis
Provide patient population that should be included in the study
Oral protein‐based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Kidney Disease 5. Renal Dialysis
Provide patient population that should be included in the study
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. End Stage Kidney Disease 4. Middle Aged 45-64 years 5. Kidney transplant 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for preventing bone disease in kidney transplant recipients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Kidney transplant 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Low Blood Pressure 7. Chronic Kidney Disease 8. Haemodialysis 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Catheter type, placement and insertion techniques for preventing catheter‐related infections in chronic peritoneal dialysis patients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. End Stage Kidney Disease 5. Middle Aged 45-64 years 6. Peritoneal Dialysis 7. Young Adult 19-24 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Alpha‐blockers as medical expulsive therapy for ureteral stones
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ureteric Stone 5. Young Adult 19-24 years 6. Ureteric Colic 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Medical and dietary interventions for preventing recurrent urinary stones in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Kidney Stone 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Chronic Kidney Disease 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Terlipressin versus other vasoactive drugs for hepatorenal syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Hepatorenal Syndrome 9. Birth to 1 mo 10. Liver cirrhosis 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Chronic Kidney Disease 8. Aged 65-79 years 9. Anemia In Chronic Kidney Disease 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Kidney transplant 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Kidney transplant 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Anemia In Chronic Kidney Disease 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for chronic kidney disease‐associated restless legs syndrome
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Restless Legs Syndrome 5. Chronic Kidney Disease
Provide patient population that should be included in the study
Steroid avoidance or withdrawal for kidney transplant recipients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Kidney transplant 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Hospitalization 7. Haemodialysis 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Normal saline versus lower‐chloride solutions for kidney transplantation
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Kidney transplant 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for lowering plasma homocysteine levels in dialysis patients
1. Adult 19-44 years 2. End Stage Kidney Disease 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Renal Dialysis
Provide patient population that should be included in the study
Laparoendoscopic single‐site donor nephrectomy (LESS‐DN) versus standard laparoscopic donor nephrectomy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Live Donor Nephrectomy
Provide patient population that should be included in the study
Antidepressants for treating depression in adults with end‐stage kidney disease treated with dialysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. End Stage Kidney Disease 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Depression 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Renal Dialysis
Provide patient population that should be included in the study
Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Haemodialysis 6. Central Venous Catheterisation 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. End Stage Kidney Disease 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Pre‐emptive correction for haemodialysis arteriovenous access stenosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Haemodialysis 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Young Adult 19-24 years 11. Surgically Constructed Arteriovenous Graft 12. Birth to 1 mo 13. Arteriovenous Fistula
Provide patient population that should be included in the study
Early versus delayed erythropoietin for the anaemia of end‐stage kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Anaemia Co-occurrent And Due To End Stage Renal Disease 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Renal Dialysis
Provide patient population that should be included in the study
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Kidney transplant 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Neutropenic Disorder 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Fungal Infection 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Citrate salts for preventing and treating calcium containing kidney stones in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Kidney Stone 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Dietary interventions for mineral and bone disorder in people with chronic kidney disease
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Kidney transplant 6. Young Adult 19-24 years 7. Chronic Kidney Disease 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Nonsteroidal anti‐inflammatory drugs (NSAIDs) and non‐opioids for acute renal colic
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Pain 4. Renal Colic 5. Young Adult 19-24 years 6. Urolith 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Haemodiafiltration, haemofiltration and haemodialysis for end‐stage kidney disease
1. Adult 19-44 years 2. End Stage Kidney Disease 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Renal Dialysis
Provide patient population that should be included in the study
Interventions for lowering plasma homocysteine levels in kidney transplant recipients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Kidney transplant 8. Young Adult 19-24 years 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Bicarbonate‐ versus lactate‐buffered solutions for acute continuous haemodiafiltration or haemofiltration
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Continuous Hemodiafiltration 7. Infant 1 to 23 mo 8. Hemofiltration 9. Acute Renal Failure 10. Young Adult 19-24 years 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Loop diuretics for patients receiving blood transfusions
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Blood Transfusion 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Belatacept for kidney transplant recipients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Kidney transplant 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral adsorbents for preventing or delaying the progression of chronic kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Chronic Kidney Disease 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Androgens for the anaemia of chronic kidney disease in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Anemia 5. Young Adult 19-24 years 6. Chronic Kidney Disease 7. Aged 65-79 years
Provide patient population that should be included in the study
Dietary interventions for preventing complications in idiopathic hypercalciuria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Idiopathic hypercalciuria 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
HMG CoA reductase inhibitors (statins) for kidney transplant recipients
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Kidney transplant 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Lipid‐lowering agents for nephrotic syndrome
1. Child, Preschool 2-5 years 2. Nephrotic Syndrome 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Percussion, diuresis, and inversion therapy for the passage of lower pole kidney stones following shock wave lithotripsy
1. Extracorporeal Shockwave Lithotripsy 2. Adult 19-44 years 3. Lower Pole Of Kidney Palpable 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Kidney Stone
Provide patient population that should be included in the study
Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Intensive Care 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Nicotine receptor partial agonists for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Exercise‐based rehabilitation programmes for pulmonary hypertension
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pulmonary Hypertension 5. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacological treatment for central sleep apnoea in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Central Sleep Apnea Syndrome 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years